BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company"))))), alongside its artificial intelligence ("AI") subsidiary InstaDeep Ltd. ("InstaDeep"), today presents an overview of its AI approach during an edition of the Company's Innovation Series, AI Day.
"At BioNTech, we are at the forefront of integrating advanced AI to revolutionize individualized medicine. With our in-house AI specialist, InstaDeep, we are pioneering the use of artificial intelligence to develop personalized vaccines and targeted therapies," said Prof. Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. "By introducing state-of-the-art technologies such as our BFN generative protein model and incorporating AI capabilities across our immunotherapy pipeline, we are unlocking the full potential of AI to deliver innovative vaccines and cancer treatments to patients worldwide".
"BioNTech and InstaDeep, as a biotechnology powerhouse with a dedicated AI unit, are uniquely positioned at the intersection of biotechnology and AI," said Karim Beguir, CEO and Co-Founder of InstaDeep, a BioNTech company. "Working closely together and combining expertise from AI research, high performance computing, software and biology is accelerating innovation. A key focus of this collaboration is our DeepChain multiomics design platform. DeepChain is now open for external partnerships, after successful application to several projects, including the mRNA-encoded antibody RiboMab platform. We are excited to harness breakthroughs in both AI and biotechnology synergistically.''
As part of the event, BioNTech will showcase the Company's approach to AI capability scaling and deployment across BioNTech's pipeline. These updates will cover the introduction of a new near exascale supercomputer, the launch of a novel BFN generative model, and multiple updates on the deployment of AI across BioNTech's immunotherapy pipeline.
The live webcast of the event will be available via this link and will begin at 3:00 pm CEST (2:00 pm BST, 9:00 am EDT). A replay of the webcast will be available shortly after the event's conclusion and archived on BioNTech's website for one year.